ADRB2 polymorphisms and budesonide/formoterol responses in COPD

Keyphrases

• Budesonide 100%
• ADRB2 Polymorphism 100%
• Gly16Arg 66%
• Formoterol 66%
• Genotype 50%
• Forced Expiratory Volume in 1 Second (FEV1) 50%
• PMDI 50%
• Dry Powder Inhaler 33%
• Adverse Events 33%
• Therapeutic Response 33%
• Severe COPD 33%
• Very Severe 33%
• Pharmacogenetic Study 33%
• ADRB2 33%
• Treatment Group 16%
• Polymorphism 16%
• Inhaled Corticosteroids 16%
• Placebo 16%
• Receptor Gene 16%
• Adrenergic Receptors 16%
• Adrenergic Agonist 16%
• Treatment Response 16%
• Acute Exacerbation of COPD (AECOPD) 16%
• Tolerability 16%
• Background Effect 16%
• Diary 16%
• Active Treatment 16%
• Long-term Treatment 16%
• Patient Treatment 16%
• Genotype Groups 16%
• Trial Registries 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Obstructive Lung Disease 100%
• Budesonide Plus Formoterol 100%
• Budesonide 66%
• Formoterol 66%
• Metered-Dose Inhaler 50%
• Dry Powder Inhaler 33%
• Adverse Event 33%
• Pharmacogenetics 33%
• Placebo 16%
• Adrenergic Receptor 16%
• Adrenergic Receptor Stimulating Agent 16%
• Tolerability 16%